O-12-M1

SUPPORTING

  • Completed phase 2 clinical trial with 45 patients
  • Included RRMM patients who had received a median of 4 prior lines of therapy, and became refractory to lenalidomide (immunomodulatory pharmaceutical – IMiD) and bortezomid (proteasome inhibitor – PI)
  • Completed enrollment late 2016 and presented final results in 2017